Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study
Second Xiangya Hospital of Central South University
Phase
Observational
Started
2025-10-27
Last updated
2026-06-02
Condition(s) studied
Diabetes MellitusDiabetes Mellitus, Type 1
Study summary
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:
1. To investigate the predictive efficacy of the genetic risk score for T1DM in determining whether diabetic patients will progress to insulin deficiency;
2. To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort.
This study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who "progressed to insulin deficiency" and those who "progressed to severe insulin deficiency". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.
Eligibility
Sex
ALL
Min age
14 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* Gender is not restricted.
* Age ranges from 14 to 50 years old.
* Diagnosis of diabetes within \< 1 year:
1. If there are diabetes symptoms and meet any of the following criteria:① Plasma glucose at any time ≥ 11.1 mmol/L (200 mg/dL), or② Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), or③ Plasma glucose 2 hours after OGTT/post - meal ≥ 11.1 mmol/L (200 mg/dL), or④ HbA1c ≥ 6.5%.
2. If there are no diabetes symptoms, another test on a different day is required for diagnosis.
* Newly - diagnosed diabetes patients whose type diagnosis is considered unclear clinically.
Exclusion Criteria:
* Peak C-peptide \< 200 pmol/L;
* Gestational diabetes, monogenic diabetes (neonatal diabetes, MODY), exocrine pancreatic diseases (cystic fibrosis), diabetes caused by drugs or chemicals;
* Those who have been under long-term treatment with hormones or immunosuppressants;
* Pregnant or lactating women;
* Those with concurrent malignant tumors or severe heart, liver, and kidney diseases;
* Those with an expected survival time of less than 3 years;
* Those with mental disorders or unable to cooperate with the investigation for other reasons;
* Acute phase of diabetic ketoacidosis;
* Stress conditions such as severe infection, fever, trauma, and major surgery;
* Patients lacking major clinical information;
* Those considered by the researcher as unfit to participate in this study.
Primary outcome measure(s)
C-peptide — "baseline"、"third year" The primary endpoint is the occurrence of progression to insulin deficiency. Subjects who "progress to insulin deficiency" are defined as those whose C-peptide level drops to C-peptide \< 250 pmol/L during the follow - up period;
Trial sites (1)
Facility
City
Region
Status
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha
Hunan
Recruiting
More Second Xiangya Hospital of Central South University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.